Open in interactive viewer → charts, metric popovers & call review

Octave's Crutch Comes Off in November

Another 35% growth quarter from Insurance Distribution — but ArmadaCare stops counting as acquired revenue, and Everspan's commercial-auto tail still isn't buried.
OSG · Earnings Call · 2026-11-10

The calendar note that matters more than the headline

On the surface this was the cleanest quarter Octave Specialty Group has produced since it reinvented itself as an MGA platform: Insurance Distribution revenue up 35% to $58 million on 23% organic growth, adjusted EBITDA to shareholders swinging to $3.3 million from negative $2.9 million, corporate expenses down to $10 million from $27 million, and net leverage under 3x. The $45 million Distribution EBITDA guide will be beaten, the $6 million Everspan guide will be met or beaten, and 2026 will be the first year of positive adjusted EPS. But the sentence that actually frames the next four quarters is an accounting footnote.

Because the ArmadaCare acquisition closed on October 31, 2025, the fourth quarter is when ArmadaCare will begin impacting our organic growth calculation. October 2026 will be the last month counted as acquired revenue.

David Trick, Chief Financial Officer · 2026-11-10
That is a genuine inflection. For four quarters, acquisition of ArmadaCare has been a load-bearing keyword in the Octave narrative — it sat near the top of the company's own keyword ranking last quarter and has now been demoted. Starting in November, the reported organic number has to be earned by the class of 2024/2025 MGAs, bolt-on teams and adjacent products, against a P&C market where “Global commercial rates declined for the ninth consecutive quarter” — Claude LeBlanc, President and Chief Executive Officer · 2026-11-10. Claude LeBlanc called the current softening a source of acquisition opportunity; the tape will judge whether it is that or simply a headwind with better branding.

What quietly fell out of the vocabulary

Three omissions are more interesting than anything management emphasised. First, the de novo launch machine has been deliberately downshifted. Prior calls were dominated by MGA launch language and a de novo class of nine; on the August call the plan was to keep 2027 modest. This quarter the growth engine is described as bolt-on teams — buying teams into existing platforms rather than standing up new ones. That is cheaper and faster, and it also means the celebrated "class of 2024/2025" contribution is now a maturing, not compounding, asset. Second, Everspan's gross premium written guidance was walked back in real time. In August: “410 our guidance. So 410 is what we're targeting. So again, I think we'll be in that range, possibly a little higher.” — Claude LeBlanc, President and CEO · 2026-08-07 On Tuesday: “our full year gross premiums written may come in slightly under our $410 million guidance.” — David Trick, Chief Financial Officer · 2026-11-10 The EBITDA guide survived; the top line did not. The reason is a mix shift toward higher-retention, higher-acquisition-cost programs, which shows up in an expense ratio of 43.5% against 28.4% a year ago, and a headline combined ratio of 100.6%. Growth at Everspan is currently being purchased. Third — and this is the oldest wound — commercial auto vaulted to the number one slot in Octave's keyword ranking this quarter, its strongest momentum reading in the set. It is not a new theme; it is a stubborn one that has appeared on and off for two years. David Trick's answer on line of sight was more concrete than usual: “the '21 and '22 books of business at this stage are pretty much closed out” — David Trick, Chief Financial Officer · 2026-11-10, with '23 and '24 running down faster. Adverse development has fallen from roughly 7% in 2025 to about 1% this year excluding the Q1 litigation settlement. The tail is shortening. It is not gone.

The argument Octave keeps having to win

For the third consecutive call, an analyst effectively asked whether AI eats the MGA. LeBlanc's framing was notably weary:

During the third quarter, the market experienced another round of concern around AI disintermediating Insurance Distribution. Our view has not changed.

Claude LeBlanc, President and Chief Executive Officer · 2026-11-10
It hasn't — back in May he was saying much the same thing, that AI would not disintermediate the MGA space “in any way, especially in the commercial or more complex specialized risk components” — Claude LeBlanc, President and CEO · 2026-05-07. What is different now is that the claim has an operating proof point rather than a slide. All MGAs are on target technology platforms, and AI driven intake is largely rolled out across the U.S., producing faster submission vetting and higher underwriting velocity. The contrarian position is worth flagging against a reporting window saturated with personal AI agents claims — from Lemonade's "emergence of personal AI agents" to Yelp's and Airbnb's agent ambitions. Most of the market is pricing AI as an intermediary-killer; Octave is one of the few specialty intermediaries arguing the opposite. Cheap talk if the operating leverage never shows up.

What the tape is and isn't saying

OSG trades at a $237 million market cap, down 14.8% over ninety days from a July peak of $6.35, though up about 31% in the last five weeks. That bounce is doing a lot of work in a chart that is still 84% below its 2014 high. Valuation is not the argument against it: price to revenue sits near 0.9x, against 14.9x at the 2022 peak, and the balance sheet has genuinely transformed — liabilities to assets have fallen to 55.5% from the mid-80s, with effective net cash of negative $72 million rather than the multi-billion hole of the guarantee era. The bear case is arithmetic, not narrative. In the last filed quarter, revenue of $83 million was up 51% year over year, yet operating income was still negative $12 million. Effective SG&A of $51 million on a $237 million market cap leaves no room for a soft organic print. The $80 million 2028 consolidated EBITDA target is the whole thesis; missing 2027 organic growth by even a few points puts it out of reach. So the story here is not the beat. It is that Octave has spent two years buying and building its way to a credible platform, and this quarter is the last one where an acquisition can disguise the organic run rate. From November, the A&H business — roughly a third of the portfolio and still pricing at double digits on medical cost inflation — has to carry a softening property and casualty cycle on its own. Management says EBITDA guidance is safe. The next two prints will tell us whether that is confidence or the last of the crutches.